All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anakinra
Therapeutic Area: Genetic Disease Product Name: Kineret
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2021
Details:
Kineret® is an interleukin-1 receptor antagonist that in the US is indicated for rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more DMARDs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Efmoroctocog alfa
Therapeutic Area: Genetic Disease Product Name: Elocta
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: National Health Service (NHS)
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2020
Details:
The National Health Service (NHS) and Sobi UK have come to an agreement that will give people living with haemophilia A in the UK increased access to Elocta (efmoroctocog alfa), by lifting prior volume restrictions for the drug.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
